When should anticoagulation be restarted after a hemorrhagic infarct, and what dosing strategy is recommended for patients with atrial fibrillation or a mechanical heart valve?

Anticoagulation After Hemorrhagic Infarct

For patients with atrial fibrillation and hemorrhagic transformation of ischemic stroke, delay anticoagulation resumption for at least 4 weeks, with optimal timing around 7-8 weeks; for mechanical heart valves, anticoagulation can be resumed earlier at 7-10 days given the higher thrombotic risk. 1, 2, 3

Critical Distinction: Location Matters

The hemorrhage location fundamentally changes your approach:

• Lobar hemorrhage: Higher recurrence risk (15% at 1 year), particularly with cerebral amyloid angiopathy. Consider avoiding warfarin entirely in these patients 1
• Deep/nonlobar hemorrhage: Lower recurrence risk (2.1% at 1 year), anticoagulation resumption more favorable 1

Timing Algorithm by Indication

For Atrial Fibrillation (Nonvalvular)

Wait 7-8 weeks before restarting anticoagulation 2. This timing balances:

• Thromboembolism risk while off anticoagulation: ~5-6% 3, 4
• Rebleeding risk after resumption: ~10-11% 3, 4

Key decision points:

• Lobar ICH: Strongly consider avoiding warfarin permanently (Class IIa recommendation) 1. DOACs may be safer alternatives, though data remain limited 1
• Nonlobar ICH: Anticoagulation resumption is reasonable after the 7-8 week window 1, 2
• CHA₂DS₂-VASc ≥4: Higher stroke risk may justify earlier resumption, but still wait minimum 4 weeks 1, 5

For Mechanical Heart Valves

Resume anticoagulation at 7-10 days post-hemorrhage 3, 4, 6. The evidence strongly supports this earlier timeline:

• Only 2 strokes occurred within 7 days off anticoagulation in a 171-patient cohort, both with additional major risk factors 3
• Pooled stroke rate while off anticoagulation: 5.2%, occurring at average 8 days 4
• Hemorrhagic recurrence after resumption: 11%, higher than ischemic stroke risk 3, 4

Critical management points:

• Avoid heparin bridging: Strongly associated with increased rebleeding risk 3
• Restart warfarin directly without bridging therapy 3
• Mitral > aortic valves: Higher thrombotic risk, may justify earlier resumption within this 7-10 day window 5, 6
• Caged-ball or tilting-disc valves: Highest risk, consider resumption closer to day 7 5

For Venous Thromboembolism

VTE within 3 months of ICH: Resume anticoagulation at 1-3 days with close monitoring, using unfractionated heparin IV initially given reversibility 5

Remote VTE history: Follow atrial fibrillation timing (7-8 weeks) 5

For Left Ventricular Thrombus/LVAD

Resume anticoagulation at 7-10 days, similar to mechanical valves given high thrombotic risk 5, 2

Dosing Strategy Upon Resumption

Warfarin

• Target INR 2.0-3.0 for atrial fibrillation 1, 7
• Target INR ≥2.5 for mechanical valves (based on valve type and position) 8, 9, 7
• Do NOT use heparin bridging - associated with 10-fold increased hemorrhagic risk 3

DOACs (for atrial fibrillation only)

• Preferred over warfarin due to lower ICH risk in general populations 7, 2
• Standard dosing recommended - no evidence for dose reduction after ICH 2
• Dabigatran, rivaroxaban, or apixaban are reasonable options 1, 7
• NOT approved for mechanical valves 7

Antiplatelet Therapy

Can restart aspirin within days after ICH (Class IIa), though optimal timing uncertain 1. Recent data from 1,916 patients showed:

• No significant increase in ICH recurrence with antiplatelet resumption 2
• Decreased thromboembolic and ischemic events 2

Risk Stratification Before Resumption

High-risk features for ICH recurrence (consider avoiding anticoagulation or using alternatives):

1. Lobar location 1
2. Multiple microbleeds on gradient-echo MRI (>5) 1
3. Cortical superficial siderosis 2
4. Apolipoprotein E ε2 or ε4 alleles 1
5. Age >75 years 1

For high-risk patients with strong anticoagulation indication:

• Left atrial appendage closure for atrial fibrillation (Class IIb) 2
• Endocardial devices require 45 days therapeutic anticoagulation post-procedure
• Epicardial devices do not require post-procedure anticoagulation 5

Common Pitfalls

1. Using heparin bridging for mechanical valves: Increases hemorrhagic complications 10-fold without reducing thrombotic events 3
2. Treating all ICH the same: Lobar vs. nonlobar location dramatically changes recurrence risk and management 1
3. Resuming too early for atrial fibrillation: The 4-week minimum is critical; 7-8 weeks is optimal 2
4. Avoiding anticoagulation indefinitely in mechanical valve patients: Thrombotic risk exceeds hemorrhagic risk after 7-10 days 3, 4
5. Using DOACs for mechanical valves: Contraindicated - dabigatran showed increased harm 7

Multidisciplinary Consultation

Involve stroke neurology, cardiology, and hematology for:

• Mechanical valve patients 10
• Lobar ICH with strong anticoagulation indication 1
• Patients with multiple microbleeds or superficial siderosis 2
• DOAC-related hemorrhage requiring reversal 10